Viruses: Cytomegalovirus (CMV); Epstein-Barr virus (EBV); hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV); herpes simplex virus (HSV-1 and HSV-2); herpes viruses 6, 7, and 8 (HHV-6, HHV-7, and HHV-8); human immunodeficiency virus (HIV); human papillomavirus (HPV); influenza virus A, influenza virus B, infl uenza (H1N1) 2009; respiratory syncytial virus (RSV); varicella-zoster virus (VZV); common cold viruses; enteroviruses; human T-lymphotropic virus (HTLV); metapneumovirus (MPV); progressive multifocal leukoencephalopathy (PML); human parainfluenza virus (HPIV); adenovirus; BK virus; JC virus; Dengue virus; arbovirus; avian influenza (H5N1); coronavirus; encephalitis viruses; West Nile virus; Saint Louis encephalitis virus; equine encephalitis viruses; rabies virus; hemorrhagic viruses; hantavirus. Markets: Influenza (H1N1) 2009 pandemic market; anti-infective market; antiviral market; market size, growth; drug classes; generics; major players, major brands; worldwide sales, market share; brands that will launch soon and achieve commercial success; market drivers and constraints. Generic competition: Public Library of Science (PLOS) studies; compulsory licenses; Brazilian Ministry of Health; patent expiry; generic antiretrovirals in sub-Saharan Africa and Brazil; Presidents Emergency Plan for AIDS Relief (PEPFAR); fi xed-dose combinations (FDCs); Indian manufacturers; access programs; HIV/AIDS; infl uenza; emergency use authorization by the FDA; World Health Organization (WHO); costs. Primary research: Survey of 100 board-certified U.S. infectious disease specialists, their insights on unmet needs and opportunities; innovative antiviral research; monoclonal antibodies (MAbs); access to antivirals; percentage of needy patients forgoing therapy; physician recommendations on what pharmaceutical companies can do to help; generic usage; pandemic preparedness. Deals: Compulsory licensing; negotiated price reductions; voluntary licenses; Gilead Access Program; life-cycle management strategies; broad-spectrum therapies; patent expiry strategy; emerging market strategy; biodefense deals; joint venture; inlicensing. Expert Contributors: Peter Wittner, principal, Interpharm Consultancy, Decision Resources Pharmaview and Pharmacor analysts. Outlook: Five things that are holding back the antiviral therapy area, five opportunities that could advance the antiviral therapy area.
Key Terms for This Report: Access programs, Antivirals, Brazil, Business development, Fixed-dose combination (FDC), Generic competition, Hepatitis, H1N1, HIV AIDS, Indian manufacturer, Least developed countries, Opportunities, Pandemic, Strategic planning, Sub-Saharan Africa
Key Topics Covered:
Executive Summary Was It Fear Mongering? Antiviral Market Competition from Generics Survey of Board-Certified U.S. Infectious Disease Specialists Select Deal Structures and Strategies Outlook Expert CommentariesCompanies Mentioned:
Abbott Laboratories Alkem Laboratories Amarillo Biosciences Asahi Kasei Pharma Aspen Pharmacare Astellas Pharma AstraZeneca Aurobindo Pharma Avexa Barr Laboratories BioAlliance Pharma BioChem Solutions BioCryst Pharmaceuticals BioPartners Boehringer Ingelheim Brazilian Ministry of Health Bristol-Myers Squibb Calmune Center of High Technologies ChemRar (CHT ChemRar) Centers for Disease Control and Prevention Chugai Pharmaceutical + many moreresearchandmarkets